Chalcone-based inhibitors against hypoxia-inducible factor 1—Structure activity relationship studies

https://doi.org/10.1016/j.bmcl.2010.10.063Get rights and content

Abstract

Many tumor tissues are under hypoxic conditions. Activating hypoxia-inducible factor 1 (HIF-1), a transcription factor, is a major mechanism for tumor cells to survive and even to evade other tissues. Therefore inhibiting HIF-1 is a potential strategy to help improve cancer treatment. Chalcone is a promising template to develop HIF-1 inhibitor because quite a few of chalcone-based compounds reveal moderate HIF-1 inhibitory activity and many chalcone-based compounds demonstrate promising anticancer activities in various animal models. However, there are no reports about the structure–activity relationship of chalcone compounds with respect to HIF-1 inhibition. This study reports the HIF-1 inhibitory activities of a panel of chalcones, identifies a few lead candidates of single-digit micromolar potency, and determines important structural modifications.

Section snippets

Acknowledgment

This investigation was partially supported by Grant R03CA125844 from National Cancer Institute, NIH (C.X.).

References and notes (19)

  • G.L. Semenza

    Drug Discovery Today

    (2007)
  • B. Manolescu et al.

    Biochimie

    (2009)
  • S. Yamazaki et al.

    Cancer Lett.

    (2002)
  • C.K. Lee et al.

    J. Pharmacol. Sci.

    (2008)
  • C.K. Lee et al.

    J. Pharmacol. Sci.

    (2006)
  • G.L. Semenza

    Oncogene

    (2010)
  • L.J. Egan et al.

    Ann. N.Y. Acad. Sci.

    (2006)
  • G.L. Semenza

    Nat. Rev. Cancer

    (2003)
  • N.T. Dat et al.

    J. Nat. Prod.

    (2009)
There are more references available in the full text version of this article.

Cited by (0)

View full text